Literature DB >> 10797633

Proton magnetic resonance spectroscopy in primary and secondary progressive multiple sclerosis.

M G Cucurella1, A Rovira, J Río, S Pedraza, M M Tintoré, X Montalbán, J Alonso.   

Abstract

The objective of this study was to characterize and compare the proton magnetic resonance spectrum of a voxel, containing lesions or normal-appearing white matter (NAWM), in primary-progressive (PP) and secondary-progressive (SP) multiple sclerosis (MS) patients. Single-voxel proton magnetic resonance spectroscopy and magnetic resonance imaging were performed in 35 MS patients (17 PP and 18 SP) and 17 controls. Spectra from an 8 ml voxel located in the parieto-occipital region were obtained with a spin-echo pulse sequence (1600 ms/135 ms/256, TR/TE/acquisitions). Resonance areas due to N-acetylaspartate (NAA), creatine/phosphocreatine (Cr) and choline compounds (Cho) were determined, and results expressed in terms of area in arbitrary units or as metabolite ratios. With respect to the control group, there were significant reductions in NAA and NAA/Cho ratio in the PP-lesion, SP-lesion, PP-NAWM and SP-NAWM groups. There were no significant differences between the PP-NAWM and SP-NAWM groups. These results support the existence of metabolic changes in the white matter of PP and SP patients and suggest that there is neuronal damage and/or loss in both clinical courses. Finally, characterization of the parieto-occipital region showed no significant differences in the spectral pattern of NAWM between PP and SP clinical courses of MS. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10797633     DOI: 10.1002/(sici)1099-1492(200004)13:2<57::aid-nbm609>3.0.co;2-5

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  7 in total

Review 1.  Imaging of multiple sclerosis: role in neurotherapeutics.

Authors:  Rohit Bakshi; Alireza Minagar; Zeenat Jaisani; Jerry S Wolinsky
Journal:  NeuroRx       Date:  2005-04

Review 2.  The role of advanced magnetic resonance imaging techniques in primary progressive MS.

Authors:  Maria A Rocca; Martina Absinta; Massimo Filippi
Journal:  J Neurol       Date:  2011-08-04       Impact factor: 4.849

3.  (1)H MR spectroscopy of the brain in multiple sclerosis subtypes with analysis of the metabolite concentrations in gray and white matter: initial findings.

Authors:  Paul E Sijens; Jop P Mostert; Matthijs Oudkerk; Jacques De Keyser
Journal:  Eur Radiol       Date:  2005-07-19       Impact factor: 5.315

4.  Quantitative cervical spinal cord 3T proton MR spectroscopy in multiple sclerosis.

Authors:  A F Marliani; V Clementi; L Albini Riccioli; R Agati; M Carpenzano; F Salvi; M Leonardi
Journal:  AJNR Am J Neuroradiol       Date:  2009-09-03       Impact factor: 3.825

5.  Serial diffusion-weighted MR imaging and proton MR spectroscopy of acute large demyelinating brain lesions: case report.

Authors:  Alex Rovira; Imma Pericot; Juli Alonso; Jordi Rio; Elisenda Grivé; Xavier Montalban
Journal:  AJNR Am J Neuroradiol       Date:  2002 Jun-Jul       Impact factor: 3.825

6.  Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study.

Authors:  Ian Marshall; Michael J Thrippleton; Mark E Bastin; Daisy Mollison; David A Dickie; Francesca M Chappell; Scott I K Semple; Annette Cooper; Sue Pavitt; Gavin Giovannoni; Claudia A M Gandini Wheeler-Kingshott; Bhavana S Solanky; Christopher J Weir; Nigel Stallard; Clive Hawkins; Basil Sharrack; Jeremy Chataway; Peter Connick; Siddharthan Chandran
Journal:  J Neurol       Date:  2018-05-30       Impact factor: 4.849

Review 7.  Quantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker.

Authors:  Kelley M Swanberg; Karl Landheer; David Pitt; Christoph Juchem
Journal:  Front Neurol       Date:  2019-11-15       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.